Show 45 earlier versions
2026-07-13
minor
Study Status, Contacts/Locations v63
Study sitesdetails revised at 1 of 35 sites
2026-07-07
minor
Study Status, Contacts/Locations v62
Study sitesdetails revised at 1 of 35 sites
2026-06-08
minor
Study Status v61
Re-verified, no change to tracked fields
2026-06-02
minor
Study Status, Contacts/Locations v60
Study sitesdetails revised at 5 of 35 sites
2026-05-12
minor
Study Status, Contacts/Locations v59
Study sitesdetails revised at 5 of 35 sites
2026-04-27
minor
Study Status, Contacts/Locations v58
2026-04-22
minor
Study Status, Contacts/Locations v57
2026-04-14
minor
Study Status, Contacts/Locations v56
Study sitesdetails revised at 1 of 33 sites
2026-04-09
minor
Study Status, Contacts/Locations v55
2026-04-07
minor
Study Status, Contacts/Locations v54
Study sitescontacts updated at 1 of 32 sites
2026-04-01
minor
Study Status, Contacts/Locations v53
2026-03-25
minor
Study Status, Contacts/Locations v52
Study sitesdetails revised at 1 of 31 sites
2026-03-17
minor
Study Status, Contacts/Locations v51
Study sitesdetails revised at 1 of 31 sites
2026-03-03
minor
Study Status, Contacts/Locations v50
Study sitesdetails revised at 1 of 31 sites
2026-02-23
minor
Study Status, Contacts/Locations v49
Study sites31 entries, revised
Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
2026-02-12
minor
Study Status, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v48
PhasePhase 1/2→Phase 2/3
Enrollment target24→74
Study sites25→31
Study arms1→3
Eligibility criteria+3 characters
[...] Rheumatology classification criteria
Diagnosis of DM, ASyS, or IMNM
Evidence of active disease, despite prior or current tr [...]
Secondary endpoints6 to 12 entries
ToIncidence evaluateof adverse events and laboratory abnormalities
To characterize the pharmacodynamicsPharmacodynamics (PD)
To characterize the pharmacokineticsPharmacokinetics (PK)
ToChange evaluatein disease-related biomarkers of muscle inflammation
ToChange evaluatein autoantibody-related biomarkers
ToProportion evaluateof efficacyDM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Propo [...]
Primary endpoints1 to 3 entries
ToPhase evaluate1/2: Incidence and severity of adverse events reported(AEs)
Phase by2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
2025-10-21
minor
Study Status, Contacts/Locations v47
Study sites25 entries, revised
Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
University of Michigan - Accepting Young Adult and Juvenile Patients
2025-10-14
minor
Study Status, Outcome Measures, Eligibility v46
Eligibility criteria-83 characters
[...] sm/American College of Rheumatology classification criteria
Presence of serum myositis-specific antibodies or myositis-associated autoantibody
Evidence of active disease, despite prior or current treatme [...]
Secondary endpointsdetails revised at 2 of 6 entries
2025-10-06
minor
Study Status, Contacts/Locations v45
Study sites25 entries, revised
Hospital for Special Surgery - Accepting Adult and Juvenile Patients
Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
2025-09-25
minor
Study Status, Contacts/Locations v44
2025-09-19
minor
Study Status, Contacts/Locations v43
2025-09-09
minor
Study Status, Arms and Interventions, Eligibility, Contacts/Locations v42
Eligibility criteria+95 characters
[...] matology classification criteria
Diagnosis of DM, ASyS, IMNM based on the presence of serum myositis-specific antibodies
Evidence of active disease, despite prior or current treatm [...] ging (MRI), or electromyography
Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
Contraindication to leukapheresis
⇅ moved History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
⇅ moved Active infection requiring medical intervention at screening
⇅ moved Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastr [...] [...]
2025-07-15
minor
Study Status, Contacts/Locations v41
Study sitescontacts updated at 1 of 17 sites
2025-07-14
minor
Study Status, Contacts/Locations v40
Study sitesdetails revised at 1 of 17 sites
2025-06-04
minor
Study Status, Contacts/Locations v39
Study sitesdetails revised at 1 of 17 sites
2025-06-03
minor
Study Status, Contacts/Locations v38
Study sitescontacts updated at 1 of 17 sites
2025-05-20
minor
Study Status, Contacts/Locations v37
Study sitesdetails revised at 2 of 17 sites
2025-05-15
minor
Study Status, Contacts/Locations v36
2025-05-14
minor
Study Status, Contacts/Locations v35
2025-05-12
minor
Study Status, Contacts/Locations v34
2025-04-30
minor
Study Status, Contacts/Locations v33
Study sitesdetails revised at 1 of 14 sites
2025-04-22
minor
Study Status, Contacts/Locations v32
Study sitescontacts updated at 1 of 14 sites
2025-04-14
minor
Study Status, Contacts/Locations v31
2025-04-10
minor
Study Status, Contacts/Locations v30
2025-02-26
minor
Study Status, Contacts/Locations v29
Study sitescontacts updated at 1 of 11 sites
2025-02-18
minor
Study Identification, Study Status, Oversight, Contacts/Locations v28
Study sitesdetails revised at 6 of 11 sites
Study titlerevised
RESET-Myositis: anAn Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects withWith Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
2025-02-06
minor
Study Identification, Study Status, Oversight, Contacts/Locations v27
Study sitesdetails revised at 7 of 11 sites
Study titlerevised
RESET-Myositis: Anan Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects Withwith Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
2024-12-20
minor
Study Identification, Study Status, Study Description, Conditions, Study Design, Arms and Interventions, Eligibility, Contacts/Locations v26
Eligibility criteria+1,479 characters
Adult Cohorts
Inclusion Criteria:
Age ≥18 and ≤75
A clinical diagnosis of [...] cant lung or cardiac impairment
Previous CAR T cell therapy
Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Juvenile Cohort
Inclusion Criteria:
Age ≥6 and ≤17 years at enrollment
A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification crit [...] Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Study description+55 characters
[...] ding dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to att [...] apy, CABA-201, that can be given to patients with DM, ASyS, andIMNM, IMNMor JIIM who have active disease.
A single dose of CABA-201 in combi [...]
Study sites11 entries, revised
University of California Irvine - Accepting Adult Patients
Mayo Clinic Florida - Accepting Adult Patients
Northwestern Memorial Hospital - Accepting Adult Patients
The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
University of Kansas Medical Center - Accepting Adult Patients
Mayo Clinic - Accepting Adult Patients
Oregon Health & Science University - Accepting Adult Patients
Vanderbilt University Medical Center - Accepting Adult Patients
Houston Methodist Hospital - Accepting Adult Patients
University of Texas MD Anderson Cancer Center - Accepting Adult Patients
[...] [...]
Study title+45 characters
[...] 201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
2024-12-13
minor
2 amendments v24-v25
2 re-verifications since 2024-12-11, no change to tracked fields
2024-12-09
minor
Study Status, Contacts/Locations v23
2024-11-27
minor
Study Identification, Study Status, Oversight, Contacts/Locations v22
Study sitesdetails revised at 6 of 10 sites
Study titlerevised
RESET-Myositis: anAn Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects withWith Active Idiopathic Inflammatory Myopathy
2024-09-13
minor
Study Status, Contacts/Locations v21
2024-09-06
minor
Study Identification, Study Status, Oversight, Contacts/Locations v20
Study sitesdetails revised at 4 of 8 sites
Study titlerevised
RESET-Myositis: Anan Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects Withwith Active Idiopathic Inflammatory Myopathy
2024-08-13
minor
Study Status, Contacts/Locations v19
Study sitescontacts updated at 1 of 8 sites